Many studies have shown that activating FXR can improve hyperglycemia and hyperlipidemia by both suppressing hepatic gluconeogenesis via FXR/miR-22-3p/PI3K/AKT/FoxO1 pathway and promoting glycogen synthesis through FXR/miR-22-3p/PI3K/AKT/GSK3β pathway (55–59). The gene discussed is NR1H4; the disease is Hyperglycemia.